
## **AMD Center of Excellence**<sup>®</sup> Medical Model – Special Testing Day



maculogix.com | +1 717.914.4067 ©2019 MacuLogix, Inc. All rights reserved. MM-166 Rev. 1



## AMD Staging, Treatment and Management Guidelines

	Subclinical AMD	Early AMD	Intermediate AMD	Advanced AMD
Functional Testing (Average Rod Intercept <sup>1</sup> )	<b>RI ≥ 6.5</b> The diagnostic specificity and sensitivity of the 6.5 minute cut-point for the presence of AMD is greater than 90%		<b>16.6</b> (+/- 5.2) orrelated with disease severity. ng AMD severity based on thes	
Structural Imaging	<ul> <li>No drusen or small drusen ≤ 63 μm</li> <li>No pigmentary abnormalities</li> </ul>	<ul> <li>Medium drusen &gt; 63 μm and ≤ 125 μm</li> <li>No pigmentary abnormalities</li> </ul>	<ul> <li>1 large druse &gt; 125 µm and/or</li> <li>Pigmentary abnormalities</li> </ul>	<ul> <li>Geographic atrophy (GA) or</li> <li>Choroidal neovascularization (CNV)</li> </ul>
Treatment Guidelines <sup>2</sup>	<ul> <li>Prescribe smoking cessation program</li> <li>Prescribe nutritional supplementation</li> <li>Discuss lifestyle modifications with respect to diet and exercise</li> <li>Discuss systemic disease management</li> <li>Prescribe blue light protection</li> <li>Prescribe UVA and UVB protection</li> </ul>	<ul> <li>Monitor smoking cessation compliance</li> <li>Monitor nutritional supplementation</li> <li>Review diet and exercise regimen</li> <li>Partner with primary care provider on systemic disease management</li> <li>Check blue light protection</li> <li>Reinforce UVA and UVB protection</li> </ul>	<ul> <li>Monitor smoking cessation compliance</li> <li>Review vitamin and supplement recommendations</li> <li>Discuss diet and exercise regimen</li> <li>Manage systemic diseases with primary care provider</li> <li>Re-evaluate optical protection</li> </ul>	<ul> <li>Low vision rehabilitation for GA</li> <li>Anti-VEGF injections for CNV</li> </ul>
Frequency of Exams	Every 6-12 months to monitor for rapid progression with clinical exam, imaging and dark adaptation testing	<b>Every 6 months</b> to monitor for rapid progression with clinical exam, imaging and dark adaptation testing	<b>Every 3-6 months</b> to monitor for CNV with clinical exam, imaging and dark adaptation testing	Refer to Retina Specialist at first sign of CNV or GA

1. Jackson, G. R., Scott, I. U., Kim, I. K., Quillen, D. A., Iannaccone, A., & Edwards, J. G. (2014). Diagnostic Sensitivity and Specificity of Dark Adaptometry for detection of Age-Related Macular Degeneration. Investigative Ophthalmology & Visual Science, 55, 1427-1431.

2. Practical Guidelines for the Treatment of AMD, published as a supplement to Review of Optometry in October, 2017

